Price increases of brand-name biotech drugs are diminishing expected savings from rival versions, called biosimilars, adding to pressure on overall health costs.

Sections:  business   
Topics:  health   
RELATED ARTICLES
    BING NEWS:
    • Biotech Roundtable: Who will bring the next CRISPR drug to market?
      Terry Chrisomalis: I believe that the next company to bring a CRISPR drug to market will be Editas Medicine (EDIT) with reni-cel, also known as EDIT-301. The reason being is because of the FDA ...
      04/2/2024 - 5:36 am | View Link
    • More

     

    Welcome to Wopular!

    Welcome to Wopular

    Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

    Senh Duong (Founder)
    Wopular, MWB, RottenTomatoes

    Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

    MoviesWithButter : Our Sister Site

    More News